{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=20", "query": { "intervention": "Placebo SC Injection", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 833, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T02:23:20.833Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04488419", "title": "ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimer Disease", "Dementia of Alzheimer Type" ], "interventions": [ { "name": "ATH-1017", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LeonaBio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 554, "start_date": "2020-09-28", "completion_date": "2024-07-15", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04488419" }, { "nct_id": "NCT02019472", "title": "A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "adalimumab 40 mg", "type": "BIOLOGICAL" }, { "name": "sirukumab 100 mg", "type": "BIOLOGICAL" }, { "name": "sirukumab 50 mg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2014-04-04", "completion_date": "2016-08-17", "has_results": true, "last_update_posted_date": "2017-10-26", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arvin", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019472" }, { "nct_id": "NCT02611830", "title": "Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colitis, Ulcerative" ], "interventions": [ { "name": "Vedolizumab 300 mg IV", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" }, { "name": "Vedolizumab 108 mg SC", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 383, "start_date": "2015-12-18", "completion_date": "2018-08-21", "has_results": true, "last_update_posted_date": "2022-05-25", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Middletown", "state": "Connecticut" }, { "city": "Inverness", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611830" }, { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT02912468", "title": "A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)" ], "interventions": [ { "name": "Dupilumab SAR231893 (REGN668)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mometasone furoate 50 micrograms", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2016-12-05", "completion_date": "2018-07-05", "has_results": true, "last_update_posted_date": "2019-07-25", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 18, "location_summary": "Long Beach, California • Orange, California • San Diego, California + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02912468" }, { "nct_id": "NCT02346240", "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2015-02-11", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 19, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346240" }, { "nct_id": "NCT06565611", "title": "A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "bremelanotide", "type": "DRUG" }, { "name": "tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Palatin Technologies, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 108, "start_date": "2024-08-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 4, "location_summary": "DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "North Charleston", "state": "South Carolina" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06565611" }, { "nct_id": "NCT03392896", "title": "Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Hyperoxaluria" ], "interventions": [ { "name": "DCR-PHXC", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 43, "start_date": "2017-12-06", "completion_date": "2019-11-19", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03392896" }, { "nct_id": "NCT04646603", "title": "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19", "ARDS, Human", "Stem Cells", "Regeneration" ], "interventions": [ { "name": "MRG-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedRegen LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-12-01", "completion_date": "2022-07-01", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04646603" }, { "nct_id": "NCT03526861", "title": "Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 301, "start_date": "2018-06-19", "completion_date": "2021-03-16", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-11-02T02:23:20.833Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526861" } ] }